hotspot -WSS

hotspot

author：comprehensive 2025-09-06 02:04:12 - browse：6

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Let's speed up science by embracing open access publishing

focus

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

New Ultima Genomics DNA sequencer can read genome for $100

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Even great ERs can’t make up for American health disparities

Juul spent big to court Black leaders to promote its e

entertainment

hotspot

knowledge

Virginia high school admissions case could be legal follow

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Trump demands the U.S. pay no more for drugs than other countries … again

Do digital therapeutics have a future in medicine?

Supreme Court strikes down use of affirmative action

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Tori Bowie and the unacceptable rates of Black maternal death

FDA's Pazdur wants cancer trials to range beyond China alone

How to save PrEP access — and even expand it

Cybersecurity threat forces Lurie Children's to take systems offline

focus

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Intellia reports positive results for its CRISPR

FDA drug safety: Singulair case shows systemic surveillance flaws

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

entertainment

focus

focus

knowledge